Compare Eni SpA (E) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Globus Medical Inc. Class A Common Stock — how do they compare? Eni SpA trades at $57.61 (market cap $82.04B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Eni SpA is far larger — about 8× Globus Medical Inc. Class A Common Stock's market cap, and Eni SpA pays a 4.25% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| E | GMED | |
|---|---|---|
Market Cap | $82.04B | $10.25B |
Volume | 245,093 | 1,108,124 |
Sector | Energy | Health |
52-Week High | $57.71 | $96.82 |
52-Week Low | $34.20 | $58.33 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $106.48B | $9.76B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.71, up 1.66% today, with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 13.35 and P/S of 0.88, though recent earnings missed expectations in Q1 and Q2 2026. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, but net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic with 34.6% analyst buy ratings and improving profitability margins. Key opportunities include Venezuela oil expansion and cost discipline, while risks involve revenue volatility and execution challenges. The stock presents value characteristics with reasonable valuation, though investors should monitor earnings consistency and global energy market conditions.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
